tooluniverse-precision-oncology

To match patient mutations to actionable cancer treatment options, this Skill integrates CIViC, ClinVar, OpenTargets, and ClinicalTrials.gov to generate evidence-graded, biomarker-driven therapy recommendations and trial matches for mutations like EGFR, KRAS, and BRAF.

Yes, you can find clinical trial eligibility based on a molecular profile. This Skill matches ongoing ClinicalTrials.gov studies to specific biomarkers and cancer types, identifying relevant trials for patients with targetable mutations or resistance scenarios.

Evidence grading for precision oncology therapies works by consolidating and ranking data from public knowledge bases like CIViC and OncoKB. This process evaluates the strength of biomarker-drug associations to propose structured, report-ready treatment plans with clear rationale.

Yes, you need access to public knowledge bases like CIViC and ClinVar to identify drug resistance treatments. The Skill integrates these external databases to analyze resistance mutations and propose alternative ranked therapies and clinical trial options.

The best way to generate a structured report for EGFR or KRAS treatment plans is to input the molecular tumor profile into this Skill. It integrates pathway analyses and trial data to output a comprehensive, report-ready plan with sources and next-step guidance.

Yes, this precision oncology approach works for both solid tumors and resistance scenarios. It applies structure-based analyses and biomarker matching across solid tumors to identify actionable treatment options for both initial mutations and acquired drug resistance.